PASG

Passage BIO, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1787297Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(46.0M)

EPS (Basic, as reported)

$-14.35

Net Margin FY2025

—

ROE FY2025

-242.7%

Total Equity

$19.0M

Shares Out

Business description

Passage BIO, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (46) → (46)

Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024⚑FY2025

Research & development————(61)(40)(23)

General & administrative(7)(30)(60)(49)(42)(25)(20)

Operating income(37)(113)(186)(138)(108)(70)(49)

Interest & investment income110————

Other income (expense), net———2664

Income tax expense—————00

Net income(46)(112)(185)(136)(102)(65)(46)

EPS — basic—($2.91)($3.48)($2.50)($1.86)($1.07)($14.35)

EPS — diluted—($2.91)($3.48)($2.50)($1.86)($1.07)($14.35)

Shares outstanding — basic (M)—39535455603

Shares outstanding — diluted (M)—39535455603

⚑ Weighted-average shares changed ÷20.00 between FY2024 and FY2025 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.